洛美利嗪抑制原代培养的脑微血管内皮细胞上P-糖蛋白的活性

目的：研究洛美利嗪对血脑屏障上P-糖蛋白功能活性的影响，寻找新型高效的P-糖蛋白抑制剂。方法：使用罗丹明123荧光指示剂研究脑微血管内皮细胞上P-糖蛋白的活性，应用RT-PCR技术分析洛美利嗪对mdr基因mRNA的影响。结果：洛美利嗪能够浓度依赖性地增加RBMECs中的罗丹明123水平，对RBMECs上mdr基因mRNA表达无影响。结论：洛美利嗪通过抑制P-糖蛋白功能活性而逆转血脑屏障上的多药耐药。     

洛美利嗪对大鼠脑微血管内皮细胞上P-糖蛋白活力的影响与P-gp及mdr1基因mRNA表达无关

目的：研究洛美利嗪对原代培养的大鼠脑微血管内皮细胞（RBMECs）上P-糖蛋白（P-gP）功能和表达的影响。方法：使用流式细胞术分析洛美利嗪对P-gp底物-罗丹明123（rhodaminel23，Rh123）在RBMECs中外排的影响，使用流式细胞术分析了洛美利嗪对RBMECs上P-gp表达的影响，应用RT-PCR技术分析了洛美利嗪对RBMECs mdr1基因mRNA水平表达的影响，还使用Transwell模型研究了洛美利嗪对Rh123通透RBMECs单层细胞转运的影响。结果：洛美利嗪通过抑制了RBMECs胞内Rh123的外排；洛美利嗪对P—gP功能的影响与RBMECs上P-gp及mdr1基因mRNA表达无关；在Transwell模型中，洛美利嗪还能显著增加Rh123跨RBMECs单层细胞膜的、经上室至下室的转运，并抑制相反方向的Rh123的转运。结论：洛美利嗪能显著地抑制RBMECs上P-gp的活性，并对P-gp底物的跨细胞转运产生影响。     

熊果酸抑制P-糖蛋白外排功能

目的研究女贞子中的熊果酸对P-糖蛋白（P-gp）功能的影响。方法用环孢素A作为P-糖蛋白功能抑制的阳性对照,用流式细胞术分析熊果酸对P-糖蛋白底物——罗丹明123在Caco-2细胞中外排的影响。结果当熊果酸浓度在0.01μmol.L-1时,实验组细胞内荧光与阴性对照组间无显著性差异（P〉0.05）;当熊果酸浓度在0.1～1μmol.L-1时,实验组细胞内荧光强度显著强于阴性对照组（P〈0.05）,并随熊果酸浓度的增高而增强;当熊果酸浓度为10μmol.L-1时,实验组细胞内荧光强度却表现为减弱,并且显著弱于阴性对照组（P〈0.05）,其原因有待后续实验探讨。结论在低浓度时（0.01μmol.L-1）,熊果酸对P-gp的功能没有影响;当熊果酸浓度在0.1～1μmol.L-1时,熊果酸对P-gp的功能有抑制作用。     

多种中草药单体对脑微血管内皮细胞内罗丹明123积累的影响

目的:寻找新型有效的血脑屏障P-糖蛋白逆转剂。方法:通过测定各化合物对牛脑微血管内皮细胞内罗丹明123积累的影响来考查它们对P-糖蛋白的功能性作用,以此筛选血脑屏障上的P-糖蛋白逆转剂。结果:各化合物浓度依赖性地增加胞内Rh123的累积浓度,作用强弱顺序为:环孢素A(CsA)>粉防己碱(Tet)>长春新碱(VCR)≈氟桂利嗪(Flu)>延胡索乙素(dl-THP)>蝙蝠葛碱(DRC)>阿齐霉素(Azi)>维拉帕米(Ver)≈小檗胺(BBM)>蝙蝠葛苏林碱(DRS)>小檗碱(BBR)>阿霉素(Dox)>左旋四氢巴马汀(l-THP)>川芎嗪(TMP)。其中CsA、Tet、Ver、Flu、Azi和dl-THP对胞内罗丹明123的累积的影响是可逆的。结论:多种中药单体,如某些异喹啉类生物碱能逆转血脑屏障上P-糖蛋白的功能,而不使血脑屏障上P-糖蛋白的固有水平发生永久性改变。     

白藜芦醇及其糖苷白藜芦醇苷与药物外排转运体的相互作用研究

目的：通过多种不同细胞模型研究两种芪类天然化合物白藜芦醇（trans-resveratrol,TR）及白藜芦醇苷（trans-piceid,TP）与多种药物外排转运体间的相互作用。方法：高效液相及荧光分光光度法分别测定细胞内TR、TP及罗丹明123的浓度,MTT比色法测定细胞活性,Western blot法测定P-糖蛋白的表达。结果：P-糖蛋白抑制剂及底物（维拉帕米和罗丹明123）对TR及TP的细胞摄取无影响。多药耐药相关蛋白2抑制剂,丙磺舒可将TR及TP的细胞摄取量分别增加1.3倍和1.6倍。TR及TP能够显著性增加大鼠脑微血管细胞对罗丹明123的摄取及阿霉素在人白血病阿霉素耐药细胞上的毒性,但对人白血病阿霉素耐药细胞上P-糖蛋白的表达没有显著性改变。米托蒽醌在人非小细胞肺癌细胞上的毒性作用不受TR及TP的影响。结论：TR及TP可以抑制P-糖蛋白的外排作用,但其本身不被P-糖蛋白外排,而是被多药耐药相关蛋白2外排。TR及TP对人乳腺癌多药耐药蛋白的外排作用没有影响。     

姜黄素对Caco-2细胞上P-糖蛋白活力及MDR1 mRNA表达的影响

目的研究姜黄素对Caco-2细胞上P-糖蛋白(P-gp)功能和表达的影响,并从分子水平研究其对MDR1mRNA表达的影响。方法采用流式细胞仪测定P-gp底物——罗丹明-123在细胞中的浓度,并分析Caco-2细胞上P-糖蛋白的表达量;采用RT-PCR法分析Caco-2细胞上MDR1基因mRNA的表达量。结果低、中、高浓度(0.1、0.5、1.0μmol.L-1)的姜黄素增加了罗丹明-123的外排,其外排量分别增加了6.2%、22.2%和33.8%(P<0.05);0.1～1.0μmol.L-1姜黄素与细胞孵育72h后,细胞膜上的荧光强度随浓度增加而增强(P<0.05),P-gp表达量是空白对照组的4倍,MDR1基因mRNA表达水平上调了1.58倍。结论姜黄素并不是P-gp的抑制剂,它能在较低浓度以及较短时间内(1h)增强Caco-2细胞上P-gp的功能活性,从而减少罗丹明-123在细胞内的蓄积。长时间(72h)应用姜黄素可以诱导P-gp和MDR1mRNA的表达。姜黄素将有可能引起相应的药物-药物/食物的相互作用。     

盐酸度洛西汀对Caco-2细胞P-糖蛋白功能及表达的影响

目的 研究盐酸度洛西汀(DLX)对Caco-2细胞上P-糖蛋白(P-gp)功能和表达的影响.方法 将Caco-2细胞分为阴性对照组、维拉帕米10 μmol/L阳性对照组(VER组)和DLX 0.2、5、10 μmol/L不同浓度处理组.采用流式细胞术检测DLX干预后Caco-2细胞内罗丹明-123的荧光强度和细胞膜上P-gP的表达量.结果 与阴性对照组相比,DLX 0.2、5、10 μmol/L均显著抑制罗丹明-123从Caco-2细胞的外排(96.3±4.5 vs.129.5±14.5、131.2±7.0、135.6±17.1)(P＜0.05),而对P-gp阳性率无明显改变(90％ vs.94％、91％、89％)(P＞0.05).结论 DLX能抑制Caco-2细胞上P-gp的功能,降低罗丹明-123从Caco-2细胞中的外排,但并不影响P-gp的表达.     

胡桃醌对血管形成的影响及其机制初探

目的：观察胡桃醌对内皮细胞系EAHY.926细胞活性和迁移性、大鼠主动脉微血管样结构和鸡胚尿囊膜血管生成的影响。方法：不同浓度胡桃醌作用于EAHY.926细胞株48 h后MTT法检测细胞存活率。大鼠主动脉无血清培养,加入100、50、25、12.5μmol/L浓度的胡桃醌,观察其对微血管结构的影响。选用7日龄鸡胚进行鸡胚绒毛尿囊膜血管生成实验。结果：200、100、50μmol/L浓度胡桃醌对EAHY.926细胞活性有明显的抑制作用（P〈0.05）,IC_（50）为122.848μmol/L;25、12.5μmol/L的胡桃醌促进EAHY.926细胞株的生长（P〈0.05）。100、50、25μmol/L的胡桃醌均可抑制大鼠主动脉微血管形成（P〈0.01）,12.5μmol/L的胡桃醌可明显减少内皮细胞的爬行数量,延缓其爬行速度（P〈0.01）。200、100、50、25μmol/L胡桃醌对鸡胚绒毛尿囊膜已存在的血管有不同程度的刺激作用,出现不同程度的充血、出血,最终凝血,且呈剂量依赖性;而12.5μmol/L的胡桃醌作用区域无新生血管形成。结论：胡桃醌具有抗血管生成作用。     

洛美利嗪对人白血病细胞K562/ADM多药耐药的逆转作用

目的：研究洛美利嗪(lomerizine，Lom)对人白血病细胞K562／ADM多药耐药逆转作用及机制。方法：使用MTT法检测Lom对K562／ADM多药耐药细胞柔红霉素(DNR)细胞毒性的影响，使用荧光分光光度计和流式细胞术分析Lom对K562／ADM多药耐药细胞胞内P—糖蛋白(P—glycoprotein，P—gp)底物—罗丹明123(rhodamine 123，Rh123)的累积情况。结果：Lom能明显提高DNR对K562／ADM多药耐药细胞的细胞毒作用，并可使胞内Rh123的浓度增加。K562敏感细胞株则不受影响。结论：Lom能显地抑制：K562／ADM多药耐药细胞上P—gp的活性，提高P—gp底物的胞内浓度，并增强其他抗癌药的细胞毒作用。     

盐酸千金藤碱逆转K562/ADR细胞多药耐药性及其机制

研究盐酸千金藤碱(cepharanthine hydrochloride,CH)逆转K562/ADR细胞多药耐药性及其机制。采用MTT法检测多柔比星(adriamycin,ADR)单用及分别与CH、维拉帕米(verapamil,VER)合用的细胞毒作用;采用流式细胞仪,测定CH对细胞内ADR蓄积、罗丹明123(Rho123)蓄积和泵出及P糖蛋白(P-gp)表达的影响。结果表明,CH(4μmol.L1)使K562/ADR细胞对ADR的敏感性增加7.43倍,逆转活性是VER的3.19倍,但对K562敏感株基本无影响。同时CH浓度依赖性地增加K562/ADR细胞内ADR和Rho123的蓄积,减少Rho123的泵出,抑制P糖蛋白的表达,但对K562细胞均无明显影响。CH在体外逆转肿瘤细胞多药耐药性的作用可能与其抑制P糖蛋白的功能和表达有关。     

HPLC法测定抗妇炎胶囊中木兰花碱、黄柏碱、药根碱、巴马汀、小檗碱、槐果碱、苦参碱、氧化槐果碱、槐定碱和氧化苦参碱

目的 采用高效液相色谱（HPLC）法同时测定抗妇炎胶囊中木兰花碱、黄柏碱、药根碱、巴马汀、小檗碱、槐果碱、苦参碱、氧化槐果碱、槐定碱和氧化苦参碱10种活性成分。方法 采用InerSustain AQ-C₁₈色谱柱（250 mm×4.6 mm,5 μm）,流动相A：乙腈–无水乙醇（80∶20）,流动相B：0.1%磷酸溶液,梯度洗脱,检测波长220 nm,体积流量1.0 mL/min,柱温30℃,进样量10 μL。结果 木兰花碱、黄柏碱、药根碱、巴马汀、小檗碱、槐果碱、苦参碱、氧化槐果碱、槐定碱和氧化苦参碱分别在2.69～134.50、1.95～97.50、0.63～31.50、0.86～43.00、11.95～597.50、0.59～29.50、6.08～304.00、4.85～242.50、1.66～83.00、19.79～989.50 μg/mL线性关系良好（r≥0.999 3）;平均回收率分别为99.11%、98.23%、96.95%、97.78%、100.02%、97.21%、99.66%、99.52%、98.81%、100.08%,RSD值分别为1.04%、1.23%、1.37%、1.65%、0.70%、1.28%、0.65%、0.81%、1.11%、0.63%。结论 建立的HPLC法可用于抗妇炎胶囊中10种活性成分的测定,作为抗妇炎胶囊质量控制方法。     

Susceptibility to erythromycin of anaerobes of the genera Bacteroides, Fusobacterium, Sphaerophorus, Veillonella, Clostridium, Corynebacterium, Peptococcus, Peptostreptococcus

The minimal inhibitory concentrations (MIC) of erythromycin were determined by broth dilution tests for 313 anaerobic strains, most of which were clinical isolates. All the gram-positive anaerobes tested (84 Peptococcaceae, including 21 Peptostreptococcus anaerobius and 15 Peptococcus variabilis; 65 Corynebacterium acnes and 29 Clostridium strains, including 13 C. perfringens) were sensitive (MIC values 0.012 through 3.12 microgram erythromycin/ml); so were 111 cultures of gram-negative anaerobes (52 Bacteroides fragilis, 12 B. thetaiotaomicron, 7 B. vulgatus, 13 B. oralis, 4 B. melaninogenicus, 10 Sphaerophorus necrophorus, 2 Veillonella sp., 11 members of other species). Erythromycin at concentrations of 6.25 through 200.0 microgram/ml was active against 24 strains (1 B. fragilis, 4 Fusobacterium fusiforme, 9 Sph. freundi, 10 Sph. varius). The present results are compared to the limited number of reports existing with regard to the susceptibility of anaerobes to erythromycin.     

Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics

Poloxamers are polyoxyethlyene, polyoxypropylene block polymers. The impurities of commercial grade Poloxamer 188, as an example, include low-molecular-weight substances (aldehydes and both formic and acetic acids), as well as 1,4-dioxane and residual ethylene oxide and propylene oxide. Most Poloxamers function in cosmetics as surfactants, emulsifying agents, cleansing agents, and/or solubilizing agents, and are used in 141 cosmetic products at concentrations from 0.005% to 20%. Poloxamers injected intravenously in animals are rapidly excreted in the urine, with some accumulation in lung, liver, brain, and kidney tissue. In humans, the plasma concentration of Poloxamer 188 (given intravenously) reached a maximum at 1 h, then reached a steady state. Poloxamers generally were ineffective in wound healing, but were effective in reducing postsurgical adhesions in several test systems. Poloxamers can cause hypercholesterolemia and hypertriglyceridemia in animals, but overall, they are relatively nontoxic to animals, with LD(50) values reported from 5 to 34.6 g/kg. Short-term intravenous doses up to 4 g/kg of Poloxamer 108 produced no change in body weights, but did result in diffuse hepatocellular vacuolization, renal tubular dilation in kidneys, and dose-dependent vacuolization of epithelial cells in the proximal convoluted tubules. A short-term inhalation toxicity study of Poloxamer 101 at 97 mg/m(3) identified slight alveolitis after 2 weeks of exposure, which subsided in the 2-week postexposure observation period. A short-term dermal toxicity study of Poloxamer 184 in rabbits at doses up to 1000 mg/kg produced slight erythema and slight intradermal inflammatory response on histological examination, but no dose-dependent body weight, hematology, blood chemistry, or organ weight changes. A 6-month feeding study in rats and dogs of Poloxamer 188 at exposures up to 5% in the diet produced no adverse effects. Likewise, Poloxamer 331 (tested up to 0.5 g/kg day(-1)), Poloxamer 235 (tested up to 1.0 g/kg day(-1)), and Poloxamer 338 (at 0.2 or 1.0 g/kg day(-1)) produced no adverse effects in dogs. Poloxamer 338 (at 5.0 g/kg day(-1)) produced slight transient diarrhea in dogs. Poloxamer 188 at levels up to 7.5% in diet given to rats in a 2-year feeding study produced diarrhea at 5% and 7.5% levels, a small decrease in growth at the 7.5% level, but no change in survival. Doses up to 0.5 mg/kg day(-1) for 2 years using rats produced yellow discoloration of the serum, high serum alkaline phosphatase activity, and elevated serum glutamicpyruvic transaminase and glutamic-oxalacetic transaminase activities. Poloxamers are minimal ocular irritants, but are not dermal irritants or sensitizers in animals. Data on reproductive and developmental toxicity of Poloxamers were not found. An Ames test did not identify any mutagenic activity of Poloxamer 407, with or without metabolic activation. Several studies have suggested anticarcinogenic effects of Poloxamers. Poloxamers appear to increase the sensitivity to anticancer drugs of multidrug-resistant cancer cells. In clinical testing, Poloxamer 188 increased the hydration of feces when used in combination with a bulk laxative treatment. Compared to controls, one study of angioplasty patients receiving Poloxamer 188 found a reduced myocardial infarct size and a reduced incidence of reinfarction, with no evidence of toxicity, but two other studies found no effect. Poloxamer 188 given to patients suffering from sickle cell disease had decreased pain and decreased hospitilization, compared to controls. Clinical tests of dermal irritation and sensitization were uniformly negative. The Cosmetic Ingredient Review (CIR) Expert Panel stressed that the cosmetic industry should continue to use the necessary purification procedures to keep the levels below established limits for ethylene oxide, propylene oxide, and 1,4-dioxane. The Panel did note the absence of reproductive and developmental toxicity data, but, based on molecular weight and solubility, there should be little skin penetration and any penetration of the skin should be slow. Also, the available data demonstrate that Poloxamers that are introduced into the body via routes other than dermal exposure have a rapid clearance from the body, suggesting that there would be no risk of reproductive and/or developmental toxicity. Overall, the available data do not suggest any concern about carcinogenesis. Although there are gaps in knowledge about product use, the overall information available on the types of products in which these ingredients are used, and at what concentration, indicates a pattern of use. Based on these safety test data and the information that the manufacturing process can be controlled to limit unwanted impurities, the Panel concluded that these Poloxamers are safe as used.     

New antiretroviral drugs: a review of the efficacy,safety, pharmacokinetics,and resistance profile of tipranavir,darunavir, etravirine,rilpivirine, maraviroc,and raltegravir

Background: The introduction and approval of new antiretroviral agents in the US and Canada bring new opportunities and new challenges. Arguably, for the first time ever, clinicians have the drugs necessary to achieve the goal of suppressing HIV RNA to levels less than 50 copies/mL in even the most treatment-experienced patients and in those with extensive drug-limiting resistance mutations. However, the use of these new agents is complicated by many drug–drug interactions and – to some extent – pre-existing mutations. To derive maximum durability from the use of these newer drugs, a thorough understanding of their indications and limitations is critical. Objective: To thoroughly review the six most recently approved or soon-to-be-approved antiretroviral drugs in the US and Canada: tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Methods: Discussion of the indications for, and pharmacokinetics, resistance profile, activity, toxicity, and clinical trials results of, the six new agents. Results/conclusions: These six new agents have resulted in marked progress towards the goal of being able to provide HIV-infected individuals with the drugs necessary to achieve decades of durable suppression of HIV without substantial toxicity.     

Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey

The physiological disposition of fluvastatin, a potent inhibitor of hydroxymethylglutaryl-CoA reductase and thus cholesterol synthesis, has been studied in the mouse, rat, dog, and monkey using 14C- or 3H-labeled drug. Oral doses of fluvastatin were absorbed at a moderate to rapid rate. The extent of absorption was dose-independent and was essentially complete in all four species studied. However, the drug was subject to extensive presystemic hepatic extraction followed by direct excretion via the bile, thus minimizing the systemic burden and yielding high liver/peripheral tissue concentration gradients for fluvastatin and its metabolites. Only at high doses far exceeding the intended human daily dose of ca 0.6 mg kg-1 did fluvastatin bioavailability approach unity, apparently due to saturation of the first-pass effect. Dose-normalized blood levels of fluvastatin and total radioactivity were higher in the dog than in the other species, suggesting a smaller distribution volume in the former. Fluvastatin was partially metabolized before excretion, the extent of metabolism being smallest in the dog and greatest in the mouse. The half-life of intact fluvastatin ranged from 1-2h in the monkey to 4-7h in the dog. Regardless of the dose or dose route, the administered radioactivity was recovered predominantly in feces, with the renal route accounting for less than 8 per cent of the dose. No tissue retention of radioactivity was observed, and material balance was essentially achieved within 96h after dosing.     

Strength of drug habits: For heroin,morphine, methadone,alcohol, barbiturates,pentobarbital, benzedrine,cocaine, and marijuana

The drug habits for 78 confirmed opiate addicts were studied on eight scales from the Process Association Test of Addiction (PATA) for many drug names. Through cluster analysis eight stages of addiction were defined: “to be clean”, “to learn about drugs”, “to hustle”, “to chip” (also “to be high”), to be psychologically dependent or “to need a shot”, “to be hooked”, “to kick a habit” and “to be in treatment”. Associations stimulated by the words heroin and morphine were very similar over the eight stages of addiction in opiate addicts. The subjects were especially inclined to associate morphine and heroin with the most severe level of addiction, “to be hooked”. Associations to both methadone and cocaine were elevated at the “hooked” stage, but in other respects associations to these drugs were opposite. Thus, associations to cocaine were focused on the stage of psychological dependence and the lower intermediate stage of addiction, “to chip” and “to be high”, whereas associations to methadone suggested a turning away from addiction as indicated by avoidance associations (“to come down” and “to kick a habit”) as well as associations to “treatment” and “to be clean”. Marijuana, Benzedrine, “goofball” (barbiturates) and alcohol habits were prominent at an intermediate stage of addiction (“to chip” and “to be high”). Avoidance associations were common for Benzedrine and “goofballs” (also pentobarbital) but not for marijuana or alcohol. “Hustling” associations were frequent for marijuana but not for alcohol.     

Simultaneous measurement of bupivacaine, etidocaine, lidocaine, meperidine, mepivacaine, and methadone

A gas-liquid chromatographic method for the simultaneous measurement of bupivacaine, etidocaine, lidocaine, meperidine, mepivacaine, and methadone in serum is described. The drugs and the internal standard, prilocaine, are extracted from 1 ml of serum. The procedure involves a two-step extraction and injection of the extract into a gas chromatograph equipped with a 10-ft OV-11 glass column and a nitrogen-phosphorus detector. The temperature gradient program results in a run time of 16 min and retention times for meperidine, prilocaine (internal standard), lidocaine, etidocaine, mepivacaine, methadone, and bupivacaine of 3.8, 5.4, 6.0, 8.7, 11.0, 11.7, and 14.8 min, respectively. Standard curves for all drugs were linear over the 80 to 2,000-ng/ml range and recovery of all components averaged 97 +/- 2% with the lowest detection limit of 10 ng/ml for all drugs except meperidine and methadone, which were 20 ng/ml. The within-day coefficients of variation ranged from 12 to 8% at 500 ng/ml. The day-to-day coefficients of variation of the slope and intercept values ranged from 2 to 0% and 130 to 3%, respectively. Response factors of the nitrogen-specific collector varied with the drug analyzed and resulted in peak area variation at constant offset and attenuation of 30%. This method is intended and adequate for therapeutic monitoring of chronically treated pain patients who are being given various combinations of local anesthetic and/or narcotic agents.     

HPLC法同时测定一清颗粒中黄芩苷等8种有效成分的含量

目的建立RP-HPLC法同时测定一清颗粒中芦荟大黄素、大黄酸、大黄素、大黄酚、大黄素甲醚、黄芩苷、汉黄芩素和盐酸小檗碱8种有效成分的含量。方法采用Kromasil C18色谱柱(250 mm×4.6 mm5,μm),以乙腈-体积分数0.1%磷酸水(三乙胺调pH值至3.0)为流动相,梯度洗脱;检测波长为254 nm,流速1.0 mL.min-1,柱温30℃。结果芦荟大黄素、大黄酸、大黄素、大黄酚、大黄素甲醚、黄芩苷、汉黄芩素和盐酸小檗碱质量浓度分别在1.800～36.20、14.25～285.1、4.500～90.01、.780～35.60、4.300～85.0、48.20～963、1.700～34.00、28.60～572.5 mg.L-1内与峰面积呈良好的线性关系(r≥0.999 1),平均回收率(n=9)分别为96.0%、98.0%、96.6%、97.0%9、7.7%9、7.0%9、7.2%9、8.0%。结论该方法快速简便、灵敏、重现性好,可为一清颗粒的质量控制提供依据。